Catalent Inc (NYSE:CTLT) – Research analysts at William Blair lowered their Q2 2018 EPS estimates for shares of Catalent in a report released on Wednesday. William Blair analyst J. Kreger now expects that the company will post earnings per share of $0.29 for the quarter, down from their prior forecast of $0.30. William Blair also issued estimates for Catalent’s Q3 2018 earnings at $0.42 EPS and Q1 2019 earnings at $0.26 EPS.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The business had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $490.75 million. During the same quarter in the prior year, the firm earned $0.16 EPS. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year.
Shares of Catalent (NYSE:CTLT) traded up $0.60 on Thursday, reaching $43.00. The company’s stock had a trading volume of 549,834 shares, compared to its average volume of 719,530. The firm has a market cap of $5,633.24, a PE ratio of 49.43, a PEG ratio of 2.69 and a beta of 1.41. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. Catalent has a fifty-two week low of $25.51 and a fifty-two week high of $43.39.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio boosted its holdings in Catalent by 1,441.4% in the third quarter. Public Employees Retirement System of Ohio now owns 41,156 shares of the company’s stock worth $1,643,000 after acquiring an additional 38,486 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Catalent by 59.0% in the third quarter. GSA Capital Partners LLP now owns 52,972 shares of the company’s stock worth $2,115,000 after acquiring an additional 19,661 shares in the last quarter. Iguana Healthcare Management LLC bought a new position in Catalent in the third quarter worth approximately $1,198,000. Colony Group LLC bought a new position in Catalent in the third quarter worth approximately $2,543,000. Finally, Neuberger Berman Group LLC boosted its holdings in Catalent by 77.3% in the third quarter. Neuberger Berman Group LLC now owns 23,025 shares of the company’s stock worth $919,000 after acquiring an additional 10,036 shares in the last quarter. 99.37% of the stock is owned by institutional investors and hedge funds.
In other Catalent news, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Research Analysts Set Expectations for Catalent Inc’s Q2 2018 Earnings (CTLT)” was posted by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.themarketsdaily.com/2018/01/13/research-analysts-set-expectations-for-catalent-incs-q2-2018-earnings-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.